Citius Pharmaceuticals Inc. Common Stock Prediction
AI-powered sentiment analysis and prediction trends for CTXR, updated each market day.
CTXR AI Sentiment
AI predicts Citius Pharmaceuticals Inc. Common stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Citius Pharmaceuticals Inc. Common
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Sector
Exchange
Market Cap
$18,863,327
Cap Tier
Employees
23
Headquarters
CRANFORD, NJ
Listed Since
Oct. 18, 2011
Website
CTXR Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CTXR Volatility
Citius Pharmaceuticals Inc. Common has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
